Last updated: March 9, 2026
What is NDC 00299-5935?
NDC 00299-5935 corresponds to VENCLEXTA (venetoclax) tablets. Developed by AbbVie, VENCLEXTA is a BCL-2 inhibitor primarily indicated for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It also has approvals for acute myeloid leukemia (AML) in combination therapies.
Market Overview
Market Size and Growth
- The global BCL-2 inhibitor market was valued at approximately $1.1 billion in 2022.
- Expected compound annual growth rate (CAGR) of 17.5% from 2023 to 2030 (Research and Markets).
- VENCLEXTA accounts for over 60% of the BCL-2 inhibitor market.
Competitor Landscape
| Product |
Manufacturer |
Indications |
Launch Year |
Market Share (2022) |
| VENCLEXTA |
AbbVie |
CLL, SLL, AML |
2016 |
60% |
| GDC-0199 (Sapacitabine) |
Genentech |
AML (Phase 3) |
2020 |
20% |
| Other agents |
Various |
Including experimental |
N/A |
20% |
Revenue Trends
- VENCLEXTA revenues grew from $402 million (2019) to $2.5 billion (2022).
- The growth reflects increased approval expansions and market penetration.
- The drug's global revenue is projected to reach $3.8 billion in 2025 as indications expand.
Pricing Dynamics
Current Market Price
- In the U.S., the average wholesale price (AWP) for a 30-tablet bottle (100 mg) is approximately $7,500.
- Per 100 mg tablet, this equates to roughly $250.
- The price varies in international markets based on regulatory and reimbursement frameworks.
Reimbursement and Payer Coverage
- VENCLEXTA enjoys formulary listing in major insurance plans in the U.S.
- Medicaid, Medicare, and private insurers typically cover the drug, often with negotiated rebates.
- Pricing in Europe averages €6,500–€8,000 per cycle, but varies per country.
Price Trends
- The price has remained relatively stable since launch, with minor adjustments based on inflation and rebate negotiations.
- Entry of biosimilars or generics is not anticipated soon due to patent protections and exclusivity periods.
Patent and Regulatory Outlook
- Patent protections for VENCLEXTA extend through 2027-2029.
- AbbVie filed for additional orphan drug designations to extend exclusivity.
- Biosimilar competition is minimal; a biosimilar approval would only impact if the formulation or patent litigation shifts.
Market Penetration and Future Projections
- Currently, VENCLEXTA penetrates approximately 75% of its target market in the U.S.
- Expansion into newly approved indications and combination therapies could increase coverage.
- By 2030, the global market for VENCLEXTA could surpass $5 billion, driven by positive trial outcomes in AML and other hematologic malignancies.
Cost and Price Implications for Stakeholders
- Manufacturers face pressure to optimize supply chain costs.
- Payers seek to balance drug efficacy with cost containment, influencing formulary decisions.
- Patients benefit from expanded access and potential biosimilar entry but face high out-of-pocket expenses without coverage.
Summary of Key Price Drivers
| Factor |
Impact |
| Patent exclusivity |
Maintains premium pricing |
| Market penetration |
Drives volume and revenue growth |
| International pricing policies |
Affect global revenue streams |
| Competitive landscape |
Limits pricing flexibility |
Key Takeaways
- NDC 00299-5935 (VENCLEXTA) is a dominant BCL-2 inhibitor with steady revenue growth.
- Current U.S. wholesale prices per 100 mg tablet are approximately $250.
- Market expansion into new indications and combination therapies anticipates revenue increase.
- Patent protections through 2027-2029 prevent generic competition, supporting current pricing.
- The global market for VENCLEXTA could surpass $5 billion by 2030.
FAQs
1. When is patent expiry for VENCLEXTA?
Patents are expected to expire around 2027–2029, depending on jurisdiction and supplementary patents.
2. Are biosimilars or generics expected soon?
No. Patent protections and exclusivity periods limit biosimilar entry until after patent expiry.
3. How does VENCLEXTA compare pricing-wise to competitors?
VENCLEXTA's price (~$7,500 per 30-tablet bottle in the U.S.) is higher than many oral cancer treatments but aligned with targeted, specialty agents.
4. What factors influence future price adjustments?
Patent status, market penetration, reimbursement negotiations, and potential biosimilar entry.
5. How are international prices differing from U.S. prices?
International prices range from €6,500 to €8,000 per cycle, often regulated by government pricing policies.
References
[1] Research and Markets. (2022). BCL-2 Inhibitors Market Analysis.
[2] IQVIA. (2022). Global Oncology Market Reports.
[3] FDA. (2016). Approval of VENCLEXTA (venetoclax).
[4] AbbVie. (2022). VENCLEXTA Annual Financial Report.
[5] MediLexicon. (2022). International drug price comparisons.
